Michael McKenna

Q-SI Operations, Inc. develops protein sequencing technologies to decode molecules life. The company was founded by Jonathan Rothberg and is headquartered in Guilford, CT.

Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.